<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-03-31">2016 March 31</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Maciej</forename><surname>Juryńczyk</surname></persName>
							<email>maciej.jurynczyk@ndcn.ox.ac.uk</email>
							<affiliation key="aff0">
								<orgName type="department">Nuffield Department of Clinical Neurosciences</orgName>
								<orgName type="institution">John Radcliffe Hospital</orgName>
								<address>
									<addrLine>Level 3, West Wing</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">University of Oxford</orgName>
								<address>
									<addrLine>Headley Way</addrLine>
									<postCode>OX3 9DU</postCode>
									<settlement>Headington, Oxford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff27">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">24 Neurology Service</orgName>
								<orgName type="institution">Medical University of Lodz</orgName>
								<address>
									<settlement>Lodz</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
							<affiliation key="aff28">
								<orgName type="institution">University Hospital of Strasbourg</orgName>
								<address>
									<settlement>Strasbourg</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brian</forename><surname>Weinshenker</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>200 First Street SW</addrLine>
									<postCode>55905</postCode>
									<settlement>Rochester</settlement>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gulsen</forename><surname>Akman-Demir</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">Istanbul Bilim University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nasrin</forename><surname>Asgari</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Institute of Molecular Medicine</orgName>
								<orgName type="institution" key="instit1">Vejle Hospital and Neurobiology</orgName>
								<orgName type="institution" key="instit2">University of Southern Denmark</orgName>
								<address>
									<settlement>Odense</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Barnes</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Atkinson Morley&apos;s Wing</orgName>
								<orgName type="institution" key="instit2">St George&apos;s Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mike</forename><surname>Boggild</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">The Townsville Hospital</orgName>
								<address>
									<addrLine>100 Angus Smith Drive, Douglas Qld 4814</addrLine>
									<settlement>Douglas, Townsville</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Abhijit</forename><surname>Chaudhuri</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Queens Hospital Rom Valley Way</orgName>
								<address>
									<postCode>RM7 0AG</postCode>
									<settlement>Romford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marie</forename><surname>D'hooghe</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">University Hospital Brussel</orgName>
								<orgName type="institution" key="instit2">Vrije Universiteit Brussel</orgName>
								<address>
									<settlement>Brussels</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nikos</forename><surname>Evangelou</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Division of Clinical Neuroscience</orgName>
								<orgName type="department" key="dep2">Queens Medical Center</orgName>
								<orgName type="institution">University of Nottingham</orgName>
								<address>
									<addrLine>Derby Road</addrLine>
									<postCode>NG7 2UH</postCode>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ruth</forename><surname>Geraldes</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Neuroscience Department</orgName>
								<orgName type="institution">Santa Maria Hospital</orgName>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="institution">University of Lisbon</orgName>
								<address>
									<settlement>Lisbon</settlement>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zsolt</forename><surname>Illes</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Institute of Clinical Research</orgName>
								<address>
									<settlement>Odense</settlement>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="institution" key="instit1">Odense University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Southern Denmark</orgName>
								<address>
									<settlement>Odense</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anu</forename><surname>Jacob</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution" key="instit1">NMO Clinical Service</orgName>
								<orgName type="institution" key="instit2">The Walton Centre</orgName>
								<address>
									<settlement>Liverpool</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ho</forename><forename type="middle">Jin</forename><surname>Kim</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">National Cancer Center</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">South Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ingo</forename><surname>Kleiter</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">St. Josef-Hospital</orgName>
								<orgName type="institution" key="instit2">Ruhr-University Bochum</orgName>
								<address>
									<settlement>Bochum</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Levy</surname></persName>
							<affiliation key="aff19">
								<orgName type="institution" key="instit1">Neuromyelitis Optica Clinic</orgName>
								<orgName type="institution" key="instit2">John Hopkins University</orgName>
								<address>
									<addrLine>1800 E. Orleans St</addrLine>
									<postCode>21287</postCode>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Romain</forename><surname>Marignier</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Service de Neurologie A</orgName>
								<orgName type="institution" key="instit1">Hopital Neurologique Pierre Wertheimer</orgName>
								<orgName type="institution" key="instit2">Hospices Civils de Lyon</orgName>
								<address>
									<postCode>69677</postCode>
									<settlement>Lyon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christopher</forename><surname>Mcguigan</surname></persName>
							<affiliation key="aff21">
								<orgName type="institution" key="instit1">University College Dublin</orgName>
								<orgName type="institution" key="instit2">St. Vincent&apos;s University Hospital</orgName>
								<address>
									<addrLine>Elm Park, Dublin 4</addrLine>
									<country key="IE">Ireland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katy</forename><surname>Murray</surname></persName>
							<affiliation key="aff22">
								<orgName type="institution" key="instit1">Anne Rowling Regenerative Neurology Clinic</orgName>
								<orgName type="institution" key="instit2">University of Edinburgh</orgName>
								<address>
									<addrLine>Chancellor&apos;s Building</addrLine>
									<postCode>EH16 4SB</postCode>
									<settlement>Edinburgh</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ichiro</forename><surname>Nakashima</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Tohoku University School of Medicine</orgName>
								<address>
									<postCode>980-8574</postCode>
									<settlement>Sendai</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lekha</forename><surname>Pandit</surname></persName>
							<affiliation key="aff24">
								<orgName type="institution">Nitte University</orgName>
								<address>
									<postCode>575018</postCode>
									<settlement>Mangalore</settlement>
									<region>Karnataka</region>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Friedemann</forename><surname>Paul</surname></persName>
							<affiliation key="aff25">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sean</forename><surname>Pittock</surname></persName>
							<affiliation key="aff26">
								<orgName type="department">Department of Neurology and Laboratory Medicine and Pathology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Krzysztof</forename><surname>Selmaj</surname></persName>
							<affiliation key="aff27">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">24 Neurology Service</orgName>
								<orgName type="institution">Medical University of Lodz</orgName>
								<address>
									<settlement>Lodz</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
							<affiliation key="aff28">
								<orgName type="institution">University Hospital of Strasbourg</orgName>
								<address>
									<settlement>Strasbourg</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jérôme</forename><surname>De Sèze</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Aksel</forename><surname>Siva</surname></persName>
							<affiliation key="aff29">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Cerrahpasa School of Medicine</orgName>
								<orgName type="institution" key="instit2">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Radu</forename><surname>Tanasescu</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Division of Clinical Neuroscience</orgName>
								<orgName type="department" key="dep2">Queens Medical Center</orgName>
								<orgName type="institution">University of Nottingham</orgName>
								<address>
									<addrLine>Derby Road</addrLine>
									<postCode>NG7 2UH</postCode>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department">Department of Neurology, Neurosurgery and Psychiatry</orgName>
								<orgName type="institution">University of Medicine and Pharmacy Carol Davila</orgName>
								<address>
									<settlement>Bucharest</settlement>
									<country key="RO">Romania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>Vukusic</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Service de Neurologie A</orgName>
								<orgName type="institution" key="instit1">Hopital Neurologique Pierre Wertheimer</orgName>
								<orgName type="institution" key="instit2">Hospices Civils de Lyon</orgName>
								<address>
									<postCode>69677</postCode>
									<settlement>Lyon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dean</forename><surname>Wingerchuk</surname></persName>
							<affiliation key="aff31">
								<orgName type="department">Division of Multiple Sclerosis and Autoimmune Neurology</orgName>
								<orgName type="institution" key="instit1">Mayo Clinic</orgName>
								<orgName type="institution" key="instit2">Mayo Clinic</orgName>
								<address>
									<addrLine>13400 E Shea BLVD</addrLine>
									<postCode>85259</postCode>
									<settlement>Scottsdale</settlement>
									<region>AZ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Damian</forename><surname>Wren</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Atkinson Morley&apos;s Wing</orgName>
								<orgName type="institution" key="instit2">St George&apos;s Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Isabel</forename><surname>Leite</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Nuffield Department of Clinical Neurosciences</orgName>
								<orgName type="institution">John Radcliffe Hospital</orgName>
								<address>
									<addrLine>Level 3, West Wing</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">University of Oxford</orgName>
								<address>
									<addrLine>Headley Way</addrLine>
									<postCode>OX3 9DU</postCode>
									<settlement>Headington, Oxford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jacqueline</forename><surname>Palace</surname></persName>
							<email>jacqueline.palace@ndcn.ox.ac.uk</email>
							<affiliation key="aff0">
								<orgName type="department">Nuffield Department of Clinical Neurosciences</orgName>
								<orgName type="institution">John Radcliffe Hospital</orgName>
								<address>
									<addrLine>Level 3, West Wing</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">University of Oxford</orgName>
								<address>
									<addrLine>Headley Way</addrLine>
									<postCode>OX3 9DU</postCode>
									<settlement>Headington, Oxford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="laboratory">Eugene Devic European Network (EDEN) and Association pour la Recherche contre la Sclerose en Plaques</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="laboratory">German Ministry for Education and Research (KKNMS Competence Network Multiple Sclerosis</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-03-31">2016 March 31</date>
						</imprint>
					</monogr>
					<idno type="MD5">AD0DBD698ED3A6AEB9D5DE0A6A3DD9A4</idno>
					<idno type="DOI">10.1007/s00415-015-7952-8</idno>
					<note type="submission">received research fellowship from the Polish Ministry of Science and Higher Education programme Mobliność Plus (1070/MOB/2013/0</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:51+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Novartis, Biogen Idec, Bayer-Schering, UCB, Eisai, Terumo BCT All demyelinating disease (CNS)</term>
					<term>Multiple sclerosis</term>
					<term>Devic&apos;s syndrome</term>
					<term>Optic neuritis</term>
					<term>Transverse myelitis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Distinguishing aquaporin-4 IgG(AQP4-IgG)-negative neuromyelitis optica spectrum disorders (NMOSD) from opticospinal predominant multiple sclerosis (MS) is a clinical challenge with important treatment implications.</s><s>The objective of the study was to examine whether expert clinicians diagnose and treat NMO/MS overlapping patients in a similar way.</s><s>12 AQP4-IgGnegative patients were selected to cover the range of clinical scenarios encountered in an NMO clinic.</s><s>27 NMO and MS experts reviewed their clinical vignettes, including relevant imaging and laboratory tests.</s><s>Diagnoses were categorized into four groups (NMO, MS, indeterminate, other) and management into three groups (MS drugs, immunosuppression, no treatment).</s><s>The mean proportion of agreement for the diagnosis was low (p o = 0.51) and ranged from 0.25 to 0.73 for individual patients.</s><s>The majority opinion was divided between NMOSD versus: MS (nine cases), monophasic longitudinally extensive transverse myelitis (LETM) (1), acute disseminated encephalomyelitis (ADEM) (1) and recurrent isolated optic neuritis (RION) (1).</s><s>Typical NMO features (e.g., LETM) influenced the diagnosis more than features more consistent with MS (e.g., short TM).</s><s>Agreement on the treatment of patients was higher (p o = 0.64) than that on the diagnosis with immunosuppression being the most common choice not only in patients with the diagnosis of NMO (98 %) but also in those indeterminate between NMO and MS (74 %).</s><s>The diagnosis in AQP4-IgG-negative NMO/MS overlap syndromes is challenging and diverse.</s><s>The classification of such patients currently requires new diagnostic categories, which incorporate lesser degrees of diagnostic confidence.</s><s>Long-term follow-up may identify early features or biomarkers, which can more accurately distinguish the underlying disorder.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>NMO, previously considered a variant of MS, is characterized by severe attacks of transverse myelitis (TM) and optic neuritis (ON) <ref type="bibr" target="#b0">[1]</ref>.</s><s>The discovery of AQP4 antibodies as a highly specific biomarker separated NMO from MS and led to its recognition as a distinct disease <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>It also broadened the clinical spectrum of NMO as AQP4 antibodies are found in limited forms of NMO such as isolated longitudinally extensive transverse myelitis (LETM), isolated optic neuritis, and in brain/brainstem syndromes previously not linked with NMO, such as the area postrema (AP) syndrome <ref type="bibr" target="#b0">[1]</ref>.</s><s>These syndromes are termed NMO spectrum disorders (NMOSD) and are managed as NMO <ref type="bibr" target="#b3">[4]</ref>.</s><s>This poses important challenges in patients who test negative for AQP4 antibodies, since most of these syndromes are not specific for NMO and are also encountered in MS or other demyelinating disorders <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>.</s><s>Accurate diagnosis is, however, essential to minimize harm from inappropriate treatment as NMO drugs are not licensed for MS and MS therapy might severely exacerbate NMO <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>.</s></p><p><s>In this study, we aimed to examine whether NMO and MS clinicians diagnose and treat antibody-negative NMO/MS overlapping patients in their everyday clinical practice in a similar way.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>Study design <ref type="bibr" target="#b26">27</ref> Neurology Consultants with expertise in inflammatory demyelinating diseases of the CNS scored 12 anonymised case histories of patients with AQP4-Ab-negative NMO or MSlike syndromes who had been referred to the Oxford NMO service.</s><s>All experts received brief clinical summaries of each patient with relevant investigation results (see Online Resource 1) and a questionnaire (see Online <ref type="bibr">Resource 2)</ref> and were asked to give their working diagnosis and how they would treat the patient in real life.</s><s>All experts were allowed to ask for additional information if they felt this would help them in their decision-making process.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical cases</head><p><s>We selected patients with clinical presentations with overlapping features of NMO and MS, because these patients pose particularly difficult diagnostic (and hence management) challenges.</s><s>Patients were selected to represent different and representative clinical dilemmas.</s></p><p><s>The clinical summaries were anonymised and contained the most relevant clinical information available such as age, sex, ethnicity, attack features, recovery from attacks, disability level, relapse and long-term treatment, laboratory test results (including myelin oligodendrocyte glycoprotein (MOG) antibody status where tested <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>), visual-evoked potentials (VEP) and brain and spinal cord MRI imaging summary reports with selected images showing lesions.</s><s>The details of these cases as sent to the clinicians are set out in Online Resource 1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis</head><p><s>Experts' opinions were categorized into four diagnostic categories (MS, NMO/NMOSD, indeterminate between MS and NMO, other) and into three treatment categories (MS disease modifying-therapies (DMTs), chronic immunosuppression (including rituximab and regular plasma exchange (PLEX), no treatment).</s><s>The main results are described qualitatively.</s></p><p><s>Proportion of observed agreement (p o ) was calculated to assess the extent to which raters agreed for an individual patient.</s><s>This was measured as the number of rater-rater pairs in agreement relative to the number of all possible rater-rater pairs <ref type="bibr" target="#b14">[15]</ref>.</s><s>A p o value of 1 corresponds to complete agreement between raters.</s><s>The lowest possible (i.e., arising by chance) p o for 27 raters and four categories is 0.22 (seven assignments to three categories and six assignments to one category), while for three categories, the lowest possible score was 0.31 (nine assignments to each category).</s></p><p><s>Mean p o and Fleiss kappa (κ) were used to assess inter-rater agreement in the whole cohort of patients <ref type="bibr" target="#b14">[15]</ref>.</s><s>κ &lt; 0 indicates poor agreement, 0.01-0.20 slight, 0.21-0.40</s><s>fair, 0.41-0.60</s><s>moderate, 0.61-0.80</s><s>substantial and 0.81-1.0</s><s>almost perfect agreement <ref type="bibr" target="#b15">[16]</ref>.</s></p><p><s>To compare kappa for treatment with kappa for diagnosis, we reduced the number of categories for diagnosis to three by merging 'indeterminate between MS and NMO' and 'other' into one category.</s></p><p><s>To assess the influence of local MS prevalence on diagnostic decisions, experts were divided into two groups: the 21 practising in countries with high MS prevalence (Australia, Belgium, Denmark, France, Germany, Ireland, Poland, United Kingdom, United States), and the six from medium or low MS prevalence countries (Portugal, Turkey, India, Japan, South Korea) <ref type="bibr" target="#b16">[17]</ref>.</s><s>Non-parametric Mann-Whitney U test was used to assess if the location of the expert influenced the likelihood of making a diagnosis of MS.</s></p><p><s>Analyses were conducted using SPSS 22.0 (SPSS Inc, Chicago, IL) and Microsoft Excel (Microsoft Corp, Redmond, WA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definition of NMO-typical and MS-typical features</head><p><s>To explore clinical and paraclinical features most strongly associated with choice, we focused on well-established discriminators between NMO and MS <ref type="bibr" target="#b4">[5]</ref>.</s><s>LETM, severe ON (i.e., with visual acuity worse than 6/36 in at least one eye at recovery), bilateral simultaneous ON, simultaneous ON and TM, NMO-like brain lesions (i.e., adjacent the floor of 3rd or 4th ventricle, periaqueductal lesions, diffuse lesions in the splenium <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>) were considered as typical of NMO, while short TM, mild ON (i.e., with visual acuity 6/36 or better at recovery), unmatched OCB in the CSF and MS-like brain lesions (lesions adjacent to lateral ventricles, Dawson's fingers, juxtacortical S-shaped lesions were considered as typical of MS and being able to distinguish MS from NMO <ref type="bibr" target="#b5">[6]</ref>).</s><s>The combination of these features was not explored because of the small numbers of cases, although integration of these observations is important in reaching a diagnosis, as none are considered either pathognomonic or exclusionary for either diagnosis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnosis</head><p><s>High disagreement among expert clinicians-Figure <ref type="figure" target="#fig_0">1</ref> shows a brief clinical summary with the different diagnoses and treatment choices scored by the experts for each patient.</s><s>Diagnoses alternative to MS and NMO ('other') included relapsing isolated ON (RION)/chronic relapsing inflammatory ON (CRION) (23 opinions), idiopathic LETM <ref type="bibr" target="#b19">(20)</ref>, acute disseminated encephalomyelitis (ADEM, 14), recurrent TM (4), neurosarcoidosis (2), vasculitis (1), Leber hereditary optic neuropathy (1), antiphospholipid syndrome (APLS, 1) and lupus <ref type="bibr" target="#b0">(1)</ref>.</s><s>NMO(SD) was the most common diagnosis in seven patients, MS in two patients and other in three patients (LETM, ADEM, CRION).</s><s>The p o for individual patients ranged from 0.25 to 0.73 (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Mean p o was 0.51 and overall Fleiss κ was 0.27 indicating fair agreement between experts.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The association between individual features and an individual clinicians</head><p><s>diagnosis-Amongst our patients, 3/12 had at least one MS-typical feature but no NMOtypical features (Table <ref type="table">2</ref>) and in these MS was diagnosed more commonly than NMO (58 % opinions versus 23.5 %, Fig. <ref type="figure" target="#fig_1">2a</ref>).</s><s>Four of 12 cases had at least one NMO-typical feature but no MS-typical features and the diagnosis of NMO was more frequent (44.4 versus 0.9 %).</s><s>Five of 12 had features typical both of MS and NMO, and NMO was diagnosed more often than MS (61.5 versus 22.9 %) demonstrating that in expert clinical assessment NMO characteristics overrode the MS-typical features.</s></p><p><s>We found that in patients with LETM (5/12), an NMO diagnosis was significantly more prevalent (60.7 % opinions) than MS (6.7 %, Fig. <ref type="figure" target="#fig_1">2b</ref>).</s><s>After excluding monophasic patients, this difference was even more striking (NMO 80.2 versus MS 9.9 %, Fig. <ref type="figure" target="#fig_1">2b</ref>).</s><s>The majority of clinicians (74 %) did not diagnose MS in patients with LETM (Online Resource 3, eTable 1).</s><s>However, short spinal cord lesions did not preclude the diagnosis of NMO by the experts.</s></p><p><s>The presence of severe residual visual loss from ON would be associated with an MS diagnosis by only 22 % of clinicians (Online Resource 3, eTable 2) and bilateral ON was associated with an MS diagnosis by only one clinician (eTable 3).</s><s>However, complete recovery from ON was felt to be compatible with NMO by the majority of clinicians (eTable 2).</s></p><p><s>Although small numbers of patients had brain MRI changes, the one patient with MS-typical lesions was diagnosed as MS by 85 % of experts and in the two cases with typical NMO lesions NMO was diagnosed by 74 % of experts, eTable 4).</s></p><p><s>The presence or absence of OCB in the CSF did not appear to strongly influence the diagnosis; 93 % of clinicians were comfortable in making at least one diagnosis of NMO in those with OCBs, and 70 % in making at least one MS diagnosis in those with absent OCBs (eTable 5).</s><s>44 % of clinicians made a diagnosis of clear NMO in monophasic disease, but another 56 % felt this was another disease.</s></p><p><s>Influence of NMO diagnostic criteria on NMO diagnosis-We further assessed how the 2006 <ref type="bibr" target="#b19">[20]</ref> (and the new 2015 <ref type="bibr" target="#b20">[21]</ref>; Table <ref type="table">3</ref>) NMO criteria impact expert diagnosis.</s><s>2006 and new NMO criteria were both fulfilled by three patients (Fig. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b10">11)</ref>.</s><s>Mean proportion of NMO diagnosis in these patients was 80 % (range 78-85 %, Table <ref type="table" target="#tab_1">4</ref>).</s><s>Alternative diagnoses included MS (9.9 % of opinions) and other (6.2 %), i.e., neurosarcoidosis, vasculitis, APLS and lupus.</s><s>Eleven experts made at least one non-NMO diagnosis in patients fulfilling the NMO criteria and 22 experts felt comfortable in diagnosing NMO in patients who did not fulfill the criteria.</s><s>For the nine patients who did not fulfill the criteria, mean proportion of NMO diagnosis varied between 4 and 63 % (Online Resource 3, eTable 6).</s><s>Only three experts fully conformed to the diagnostic criteria in their answers.</s></p><p><s>Sources of diagnostic disagreement-Experts' comments have been analyzed to identify sources of disagreement in cases with most diverse diagnoses (i.e., six patients characterized by a p o &lt; 0.5).</s><s>In five of these cases, experts disagreed mainly between NMO and MS and in one case (patient 12) mainly between NMO and ADEM.</s><s>Sources of disagreement are presented in Table <ref type="table" target="#tab_1">4</ref>.</s><s>The sources of disagreement varied between the cases; patient 5 and 9 had mixed typical features of both MS and NMO, patient 4 had typical clinical MS features not backed by brain MRI, and patient 3 had brain lesions not completely typical of NMO or MS and a spinal cord lesion of approximately three vertebral segments that would be considered indeterminate or borderline (Fig. <ref type="figure" target="#fig_2">3</ref>).</s></p><p><s>We were also interested to see whether local MS prevalence might have influenced experts' diagnostic decisions.</s><s>We found that experts from countries characterized by low or medium MS prevalence diagnosed MS less frequently than those from areas with high prevalence of MS (Online Resource 4, p = 0.01).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment</head><p><s>Treatment recommendations-We further analyzed how experts would manage these patients.</s><s>In the total cohort of 12 patients, 64.8 % of opinions recommended immunosuppression, 18.8 % DMTs and 16.4 % none (or 'watch and wait').</s><s>Treatment options for individual patients are shown in Fig. <ref type="figure" target="#fig_0">1</ref>.</s><s>Mean p o for treatment was 0.64 and κ was 0.30 (Online Resource 3, eTable 7).</s><s>After reducing the number of categories to three for diagnosis (MS, NMO, indeterminate/other), we found that both mean p o and inter-rater κ for treatment are higher in comparison to those for diagnosis (mean p o for three diagnostic categories 0.53, κ 0.26).</s><s>Thus, experts appeared to agree more on the management of patients than on the diagnosis often choosing immunosuppression as the preferred option.</s></p><p><s>How the diagnosis affects the treatment choice-Where a diagnosis of NMO was made, immunosuppression was selected in 97 % of cases whereas a no treatment strategy was selected in the remainder.</s><s>Where MS was diagnosed, 73 % opinions pointed to DMTs, 18 % to immunosuppression and 9 % to no treatment.</s><s>If MS DMTs were selected, first-line MS drugs (IFN-β, glatiramer) were generally preferred (79 %) to second-line drugs (natalizumab, fingolimod).</s><s>In patient 3 who had an aggressive disease with active brain lesions, ten experts diagnosed MS and of these the majority went for second-line DMTs.</s><s>Where the diagnosis was indeterminate between MS and NMO (27 opinions, 9/12 patients), immunosuppression was selected in 74 % of opinions, no treatment in 22 % and DMTs in 4 %.</s><s>In two patients who had monophasic disease, 28 % of opinions suggested chronic treatment with immunosuppression (26 %) or MS DMT (2 %).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Our study shows that experts frequently disagreed on the diagnosis of AQP4-Ab-negative NMO/MS overlapping patients.</s><s>The majority opinion was divided between MS versus NMO(SD), but also NMOSD versus monophasic LETM <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>, NMOSD versus RION/ CRION, and NMOSD versus ADEM.</s><s>The presence of typical NMO features, such as LETM or severe ON, was associated with a low rate of MS diagnosis, even if MS features were also present.</s><s>When NMO features occurred without MS features, experts often pointed to diagnoses alternative to NMO(SD), such as CRION, or in monophasic patients ADEM or idiopathic LETM.</s><s>There was a lack of consensus on diagnosis of monophasic syndromes consistent with NMOSD.</s><s>Some consultants considered them as indeterminate monophasic events (LETM, ADEM), while others diagnosed NMOSD.</s><s>NMO was typically diagnosed in those who fulfilled NMO criteria but it was also considered in those who did not fulfill them.</s><s>Immunosuppression was the first-choice treatment in almost all NMO(SD) patients, most patients indeterminate between MS and NMO, and also in some MS patients.</s><s>MS DMTs were typically recommended in patients with the diagnosis of MS but were generally avoided in patients indeterminate between NMO and MS.</s></p><p><s>Frequent disagreement among experts regarding the diagnosis indicates that borders between AQP4-negative NMOSD and other inflammatory conditions of the CNS are poorly demarcated.</s><s>This also reflects the wide differential in antibody-negative NMOSD <ref type="bibr" target="#b12">[13]</ref>.</s><s>Combinations of NMO and MS features (e.g., severe ON and short TM) are not uncommon in patients referred to an NMO clinic and if strong NMO/MS discriminators are lacking, accurate diagnosis is challenging.</s></p><p><s>Not surprisingly, LETM is a potent NMO/MS discriminator and it strongly drives the diagnosis toward NMO(SD), particularly if it occurs in the context of a relapsing disease.</s><s>But this is dependent on availability of spinal cord imaging at the time of an acute myelitis event; imaging in remission may fail to demonstrate a LETM.</s><s>It is also worth emphasizing that a number of different diseases can cause LETM <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>.</s><s>In a recent large series of LETM patients presenting to an NMO service, diagnoses alternative to NMO could be identified even in those fulfilling the NMO diagnostic criteria, and only 6.5 % of patients had "true" seronegative NMO and 6.5 % had idiopathic LETM <ref type="bibr" target="#b22">[23]</ref>.</s><s>On the other hand, the initial myelitis episode in NMO(SD) is accompanied by a short lesion in approximately 14 % of AQP4-Ab-positive cases <ref type="bibr" target="#b23">[24]</ref>, which might explain frequent NMO diagnoses in short TM patients in our study.</s><s>While relapsing AQP4-Ab-negative disease with LETM is generally considered within the NMO(SD), relapsing severe ON is often recognized as distinct from NMOSD and termed RION or CRION by many experts <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s>Interestingly, CSF OCB was not strongly influential and this is probably because other features were felt to be more important.</s></p><p><s>Fulfillment of the diagnostic criteria was not considered obligatory by the majority of experts (89 %) and individual raters appeared to have different thresholds for overriding them.</s><s>Some experts accepted spinal cord lesions shorter than three segments or abnormal brain MRI which would fulfill Paty criteria as compatible with NMO <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b26">27]</ref>.</s><s>Also typical NMO-like brain lesions appeared to override other criteria in some cases.</s></p><p><s>Despite diagnostic difficulties experts tend to agree that when there is a serious doubt about the diagnosis and NMO is a possibility, immunosuppression is the most prudent option.</s><s>This might explain frequent decisions to use this modality to treat not only indeterminate cases but also those diagnosed with MS.</s><s>This approach reflects a general opinion supported by several reports that MS drugs (notably interferon β, natalizumab and fingolimod) might dramatically exacerbate NMO <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref>, whereas there is evidence that immunosuppression might be efficacious in MS <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref>.</s><s>The drugs most commonly used for overlap syndromes in our clinical practice include azathioprine, mycophenolate and rituximab.</s></p><p><s>There are several limitations to this study.</s><s>First of all, the quantitative analysis cannot be applied to other clinical settings because the patients were pre-selected to cover a range of challenging clinical scenarios and are not representative of unselected MS or NMO clinic populations.</s><s>However, this study was deliberately exploring the agreement of experts within this selected group of patients.</s><s>The local prevalence of differential diagnosis might have affected how experts rated our cases and therefore could have contributed to the disagreement.</s><s>This was supported by the observation that experts from countries with low or medium MS prevalence less frequently diagnosed MS compared with those from high MS prevalence areas.</s><s>Of note, the predictive value of diagnostic criteria in general depends on the local prevalence rates of the condition.</s><s>Another concern could be that clinical vignettes provide limited information on patients in comparison to a face-to-face experience and full access to medical records.</s><s>This approach should not, however, increase the disagreement as all experts were presented with the same information, which would more likely reduce variation produced by differences in individual experts' clinical experience and style.</s><s>Despite its possible limitations, well-constructed clinical vignettes are considered the best tool to evaluate the clinical practice in real-life settings and to perform comparative analysis among medical centers or health care systems <ref type="bibr" target="#b34">[35]</ref>.</s></p><p><s>Significant disagreement on the diagnosis of AQP4-Ab-negative NMO/MS overlapping syndromes has important therapeutic implications as treatments for both diseases differ and with a rapid progress in the field of MS/NMO therapy, they are likely to become even more exclusive in the upcoming years.</s><s>More work is required to subdivide AQP4-Ab-negative NMOSD so that clinicians could clearly classify patients according to phenotype with more  a Mean proportion of distinct diagnoses in patients who had at least one MS-typical feature but none of NMO-typical features, those who had at least one NMO-typical feature but none of MS-typical features and those who had both types of features (as in Table <ref type="table">2</ref>).</s><s>b.</s><s>Mean proportion of distinct diagnoses in patients who had LETM, patients who had LETM as a part of a relapsing disease and those who had ON with poor recovery  Agreement table for diagnosis with the number of ratings for individual patients and measures of inter-rater agreement</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Short descriptions of patients' clinical presentation and 100 % stacked bar charts showing variability of opinions concerning the diagnosis and treatment of patients</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s></p></div></figDesc><graphic coords="12,156.72,62.00,358.56,504.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. Examples of MRI images with mixed features of MS and NMO.</s><s>Patient 3 had borderline LETM (a, arrow) and a gadolinium-enhancing well-demarcated juxtacortical lesion not typical of NMOSD (b, arrow).</s><s>Patient 5 had a central spinal cord lesion shorter than three segments (c, arrow) and a lesion in the floor of 4th ventricle considered typical of NMOSD by most experts (d).</s><s>All MRI images, which were available for experts, are included in Online Resource 1</s></p></div></figDesc><graphic coords="14,155.64,62.00,360.72,397.18" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc><div><p><s>Bold values indicate inter-rater agreement parameters for the whole cohort of patients</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 4</head><label>4</label><figDesc><div><p><s>Clinical presentations associated with very low agreement (p o &lt; 0.5) on the diagnosis ON with limited recovery and short TM Mild ON and short TM with normal brain MRI ON and borderline LETM ON and TM with brain lesions not fully typical of MS or NMO Monophasic ADEM-like disease with ON and LETM</s></p></div></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J Neurol. Author manuscript; available in PMC 2016March 31.   </note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>agreement.</s><s>This could be instituted by allowing different degrees of certainty such as 'possible', 'probable' or using other terms such as 'undefined' or 'mixed', and would be particularly useful in monophasic phenotypes with short follow-up times and in those with mixed NMO and MS features.</s><s>Limited forms of NMO (NMOSD), which are particularly challenging, are currently not recognized by NMO criteria.</s><s>However, it is clear from this study that clinicians regard limited forms of NMO as a similar entity to this with both ON and TM.</s><s>MOG Abs identified in some AQP4-Ab-ve patients might define a distinct, probably milder form of NMO and help differentiating it from MS <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b35">36]</ref>.</s><s>In those who are double negative, the accurate diagnosis may demand longitudinal follow-up.</s><s>Further prospective studies on patients defined both on clinical/radiological characteristics and serology results are needed to develop diagnostic algorithms and determine the ultimate diagnosis in this group of patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Material</head><p><s>Refer to Web version on PubMed Central for supplementary material.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 2</head><p><s>The presence of typical MS-like and NMO-like features in 12 cases selected for the project</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The spectrum of neuromyelitis optica</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Wingerchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Lucchinetti</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1474-4422(07)70216-8</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="805" to="815" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17706564</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">A serum autoantibody marker of neuromyelitis optica</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Lennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Wingerchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Kryzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="2106" to="2112" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15589308</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Lennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Kryzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Pittock</surname></persName>
		</author>
		<idno type="DOI">10.1084/jem.20050304</idno>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="473" to="477" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 16087714</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">A practical guide to the treatment of neuromyelitis optica</title>
		<author>
			<persName><forename type="first">J</forename><surname>Palace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Leite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Leite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jacob</surname></persName>
		</author>
		<idno type="DOI">10.1136/practneurol-2012-000237</idno>
	</analytic>
	<monogr>
		<title level="j">Pract Neurol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="209" to="214" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22869762</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Overlapping CNS inflammatory diseases: differentiating features of NMO and MS</title>
		<author>
			<persName><forename type="first">M</forename><surname>Juryńczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Craner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Palace</surname></persName>
		</author>
		<idno type="DOI">10.1136/jnnp-2014-308984</idno>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="20" to="25" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25248365</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution</title>
		<author>
			<persName><forename type="first">L</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Marasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jenkinson</surname></persName>
		</author>
		<idno type="DOI">10.1212/01.wnl.0000436079.95856.1f</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="1330" to="1337" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23486868</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers</title>
		<author>
			<persName><forename type="first">J</forename><surname>Palace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Leite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nairne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vincent</surname></persName>
		</author>
		<idno type="DOI">10.1001/archneurol.2010.188</idno>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1016" to="1017" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20697055</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kleiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hellwig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berthele</surname></persName>
		</author>
		<idno type="DOI">10.1001/archneurol.2011.216</idno>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="239" to="245" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22332191</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Does Natalizumab Therapy Worsen Neuromyelitis Optica?</title>
		<author>
			<persName><forename type="first">A</forename><surname>Jacob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Optica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="1065" to="1069" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22914835</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Natalizumab and the development of extensive brain lesions in neuromyelitis optica</title>
		<author>
			<persName><forename type="first">M</forename><surname>Juryńczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zaleski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Selmaj</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00415-013-6965-4</idno>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">260</biblScope>
			<biblScope unit="page" from="1919" to="1921" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23719787</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder</title>
		<author>
			<persName><forename type="first">J-H</forename><surname>Min</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<idno type="DOI">10.1177/1352458511431973</idno>
	</analytic>
	<monogr>
		<title level="j">Mult Scler J</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="113" to="115" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kitley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodhall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Waters</surname></persName>
		</author>
		<idno type="DOI">10.1212/WNL.0b013e31826aac4e</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="1273" to="1277" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22914827</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kitley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Waters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodhall</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamaneurol.2013.5857</idno>
		<ptr target="JAMANeurol.201410.1001/jamaneurol.2013.5857" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Callegaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lana</forename><forename type="middle">-</forename><surname>Peixoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename></persName>
		</author>
		<idno type="DOI">10.1212/WNL.0000000000000101</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="474" to="481" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24415568</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Measuring nominal scale agreement among many raters</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Fleiss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychol Bull</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="378" to="382" />
			<date type="published" when="1971">1971</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The measurement of observer agreement for categorical data</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Landis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Koch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrics</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="159" to="174" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
	<note>PubMed: 843571</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">The changing demographic pattern of multiple sclerosis epidemiology</title>
		<author>
			<persName><forename type="first">N</forename><surname>Koch-Henriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Sørensen</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1474-4422(10)70064-8</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="520" to="532" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20398859</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Magnetic resonance imaging in neuromyelitis optica</title>
		<author>
			<persName><forename type="first">G</forename><surname>Tackley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kuker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Palace</surname></persName>
		</author>
		<idno>1177/1352458514531087</idno>
	</analytic>
	<monogr>
		<title level="j">Mult Scler</title>
		<imprint>
			<date>201410</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">MRI characteristics of neuromyelitis optica spectrum disorder: an international update</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lana</forename><forename type="middle">-</forename><surname>Peixoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename></persName>
		</author>
		<idno type="DOI">10.1212/WNL.0000000000001367</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="1165" to="1173" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25695963</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Revised diagnostic criteria for neuromyelitis optica</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Wingerchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Lennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Pittock</surname></persName>
		</author>
		<idno type="DOI">10.1212/01.wnl.0000216139.44259.74</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1485" to="1489" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 16717206</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">International consensus diagnostic criteria for neuromyelitis optica spectrum disorders</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Wingerchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Banwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bennett</surname></persName>
		</author>
		<idno type="DOI">10.1212/WNL.0000000000001729</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="177" to="189" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 26092914</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The differential diagnosis of longitudinally extensive transverse myelitis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Kitley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Leite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Palace</surname></persName>
		</author>
		<idno type="DOI">10.1177/1352458511406165</idno>
	</analytic>
	<monogr>
		<title level="j">Mult Scler</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="271" to="285" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 21669935</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kitley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Leite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Küker</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamaneurol.2013.3890</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA Neurol</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1375" to="1381" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23999580</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Short myelitis lesions in aquaporin-4-IgGpositive neuromyelitis optica spectrum disorders</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Flanagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Weinshenker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Krecke</surname></persName>
		</author>
		<idno>10.1001/ jamaneurol.2014.2137</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA Neurol</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="81" to="87" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25384099</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Chronic relapsing inflammatory optic neuropathy (CRION)</title>
		<author>
			<persName><forename type="first">D</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Burton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Plant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Graham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="276" to="284" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12538397</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported</title>
		<author>
			<persName><forename type="first">A</forename><surname>Petzold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Plant</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00415-013-6957-4</idno>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">261</biblScope>
			<biblScope unit="page" from="17" to="26" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 23700317</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Paty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Oger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Kastrukoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="180" to="185" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note>PubMed: 3340277</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Immunosuppressive therapy is more effective than interferon in neuromyelitis optica</title>
		<author>
			<persName><forename type="first">C</forename><surname>Papeix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-S</forename><surname>Vidal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De Seze</surname></persName>
		</author>
		<idno type="DOI">10.1177/1352458506070732</idno>
	</analytic>
	<monogr>
		<title level="j">Mult Scler</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="256" to="259" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17439893</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese</title>
		<author>
			<persName><forename type="first">T</forename><surname>Matsuoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Matsushita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kawano</surname></persName>
		</author>
		<idno type="DOI">10.1093/brain/awm027</idno>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1206" to="1223" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17439988</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Itoyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kikuchi</surname></persName>
		</author>
		<idno type="DOI">21.10.1186/1471-2377-14-21</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Neurol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24475777</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">New treatments and azathioprine in multiple sclerosis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Palace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rothwell</surname></persName>
		</author>
		<idno type="DOI">261.10.1016/S0140-6736(97)24030-4</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9242805</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients</title>
		<author>
			<persName><forename type="first">L</forename><surname>Michel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vukusic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Seze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<idno>10.1136/ jnnp-2013-305298</idno>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="279" to="283" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 23704316</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Goodkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rudick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vanderbrug</forename><surname>Medendorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.1002/ana.410370108</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="30" to="40" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 7818255</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">B-cell depletion with rituximab in relapsing-remitting multiple sclerosis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Hauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Waubant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Arnold</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa0706383</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="page" from="676" to="688" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18272891</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Measuring the quality of physician practice by using clinical vignettes: a prospective validation study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Peabody</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Luck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Glassman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="771" to="780" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15545677</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">MOG cell-based assay detects non-MS patients with inflammatory neurologic disease</title>
		<author>
			<persName><forename type="first">P</forename><surname>Waters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodhall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol Neuroimmunol Neuroinflam</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">e89</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
